Aimmune Therapeutics Inc (NASDAQ:AIMT)’s share price shot up 11.6% during mid-day trading on Wednesday . The stock traded as high as $22.06 and last traded at $24.62, 140,179 shares were traded during trading. A decline of 79% from the average session volume of 661,346 shares. The stock had previously closed at $22.06.

A number of research analysts have commented on AIMT shares. Royal Bank of Canada dropped their price objective on shares of Aimmune Therapeutics to $50.00 and set an “outperform” rating on the stock in a research note on Friday, August 9th. BidaskClub downgraded Aimmune Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, August 24th. Stifel Nicolaus reissued a “hold” rating on shares of Aimmune Therapeutics in a report on Wednesday. Roth Capital started coverage on Aimmune Therapeutics in a research note on Friday, July 12th. They set a “buy” rating and a $45.00 price target for the company. Finally, Credit Suisse Group started coverage on Aimmune Therapeutics in a report on Tuesday, May 21st. They set an “outperform” rating and a $30.00 price target for the company. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and six have given a buy rating to the company. Aimmune Therapeutics has an average rating of “Buy” and a consensus price target of $41.38.

The company has a 50-day simple moving average of $19.94 and a 200-day simple moving average of $20.82. The stock has a market cap of $1.24 billion, a PE ratio of -6.83 and a beta of -0.09. The company has a debt-to-equity ratio of 0.24, a current ratio of 5.80 and a quick ratio of 5.80.

Aimmune Therapeutics (NASDAQ:AIMT) last issued its earnings results on Thursday, August 8th. The biotechnology company reported ($1.01) EPS for the quarter, missing the consensus estimate of ($0.93) by ($0.08). During the same period in the prior year, the firm posted ($0.91) EPS. On average, equities analysts expect that Aimmune Therapeutics Inc will post -4 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently modified their holdings of AIMT. Price T Rowe Associates Inc. MD raised its position in Aimmune Therapeutics by 11.4% during the second quarter. Price T Rowe Associates Inc. MD now owns 5,246,604 shares of the biotechnology company’s stock worth $109,234,000 after acquiring an additional 535,072 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Aimmune Therapeutics by 4.6% in the second quarter. Vanguard Group Inc. now owns 3,706,394 shares of the biotechnology company’s stock valued at $77,167,000 after purchasing an additional 164,038 shares during the last quarter. FMR LLC increased its stake in shares of Aimmune Therapeutics by 30.3% during the 1st quarter. FMR LLC now owns 2,734,583 shares of the biotechnology company’s stock worth $61,117,000 after purchasing an additional 635,362 shares in the last quarter. Victory Capital Management Inc. increased its stake in shares of Aimmune Therapeutics by 2.4% during the 2nd quarter. Victory Capital Management Inc. now owns 1,121,811 shares of the biotechnology company’s stock worth $23,357,000 after purchasing an additional 26,690 shares in the last quarter. Finally, Rice Hall James & Associates LLC raised its position in shares of Aimmune Therapeutics by 31.1% during the 2nd quarter. Rice Hall James & Associates LLC now owns 669,560 shares of the biotechnology company’s stock worth $13,940,000 after purchasing an additional 158,851 shares during the last quarter. 78.06% of the stock is currently owned by hedge funds and other institutional investors.

Aimmune Therapeutics Company Profile (NASDAQ:AIMT)

Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy.

Read More: How can investors benefit from after-hours trading?

Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.